These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 16035081)

  • 1. Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease.
    Planinsic RM; van der Meer J; Testa G; Grande L; Candela A; Porte RJ; Ghobrial RM; Isoniemi H; Schelde PB; Erhardtsen E; Klintmalm G; Emre S
    Liver Transpl; 2005 Aug; 11(8):895-900. PubMed ID: 16035081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation.
    Lodge JP; Jonas S; Jones RM; Olausson M; Mir-Pallardo J; Soefelt S; Garcia-Valdecasas JC; McAlister V; Mirza DF;
    Liver Transpl; 2005 Aug; 11(8):973-9. PubMed ID: 16035095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant activated factor VII in spinal surgery: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial.
    Sachs B; Delacy D; Green J; Graham RS; Ramsay J; Kreisler N; Kruse P; Khutoryansky N; Hu SS
    Spine (Phila Pa 1976); 2007 Oct; 32(21):2285-93. PubMed ID: 17906567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activated recombinant factor VII in orthotopic liver transplantation.
    Pugliese F; Ruberto F; Summonti D; Perrella S; Cappannoli A; Tosi A; D'alio A; Bruno K; Martelli S; Celli P; Morabito V; Rossi M; Berloco PB; Pietropaoli P
    Transplant Proc; 2007; 39(6):1883-5. PubMed ID: 17692642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant factor VIIa reduces transfusion requirements in liver transplant patients with high MELD scores.
    Niemann CU; Behrends M; Quan D; Eilers H; Gropper MA; Roberts JP; Hirose R
    Transfus Med; 2006 Apr; 16(2):93-100. PubMed ID: 16623915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant activated factor VII in patients with acute liver failure with UNOS Status 1A: a single tertiary academic centre experience.
    Pham HP; Hsu SX; Parker-Jones S; Samstein B; Diuguid D; Schwartz J
    Vox Sang; 2014 Jan; 106(1):75-82. PubMed ID: 23815226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: a double-blind, randomized, placebo-controlled trial.
    Raobaikady R; Redman J; Ball JA; Maloney G; Grounds RM
    Br J Anaesth; 2005 May; 94(5):586-91. PubMed ID: 15734783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry.
    Parameswaran R; Shapiro AD; Gill JC; Kessler CM;
    Haemophilia; 2005 Mar; 11(2):100-6. PubMed ID: 15810910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and hemostatic effect of recombinant activated factor VII in cirrhotic patients undergoing partial hepatectomy: a multicenter, randomized, double-blind, placebo-controlled trial.
    Shao YF; Yang JM; Chau GY; Sirivatanauksorn Y; Zhong SX; Erhardtsen E; Nivatvongs S; Lee PH
    Am J Surg; 2006 Feb; 191(2):245-9. PubMed ID: 16442954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency.
    Brenner B; Wiis J
    Hematology; 2007 Feb; 12(1):55-62. PubMed ID: 17364994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is the use of rFVIIa safe and effective in bleeding neonates? A retrospective series of 8 cases.
    Mitsiakos G; Papaioannou G; Giougi E; Karagianni P; Garipidou V; Nikolaidis N
    J Pediatr Hematol Oncol; 2007 Mar; 29(3):145-50. PubMed ID: 17356391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials.
    Boffard KD; Riou B; Warren B; Choong PI; Rizoli S; Rossaint R; Axelsen M; Kluger Y;
    J Trauma; 2005 Jul; 59(1):8-15; discussion 15-8. PubMed ID: 16096533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elective administration in infants of low-dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypass surgery for congenital heart disease does not shorten time to chest closure or reduce blood loss and need for transfusions: a randomized, double-blind, parallel group, placebo-controlled study of rFVIIa and standard haemostatic replacement therapy versus standard haemostatic replacement therapy.
    Ekert H; Brizard C; Eyers R; Cochrane A; Henning R
    Blood Coagul Fibrinolysis; 2006 Jul; 17(5):389-95. PubMed ID: 16788315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study.
    Hendriks HG; Meijer K; de Wolf JT; Klompmaker IJ; Porte RJ; de Kam PJ; Hagenaars AJ; Melsen T; Slooff MJ; van der Meer J
    Transplantation; 2001 Feb; 71(3):402-5. PubMed ID: 11233901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants of complications with recombinant factor VIIa for refractory blood loss in cardiac surgery.
    Karkouti K; Yau TM; Riazi S; Dattilo KM; Wasowicz M; Meineri M; McCluskey SA; Wijeysundera DN; van Rensburg A; Beattie WS
    Can J Anaesth; 2006 Aug; 53(8):802-9. PubMed ID: 16873347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25 degrees C stable formulation.
    Bysted BV; Scharling B; Møller T; Hansen BL
    Haemophilia; 2007 Sep; 13(5):527-32. PubMed ID: 17880439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Control of bleeding in children with Dengue hemorrhagic fever using recombinant activated factor VII: a randomized, double-blind, placebo-controlled study.
    Chuansumrit A; Wangruangsatid S; Lektrakul Y; Chua MN; Zeta Capeding MR; Bech OM;
    Blood Coagul Fibrinolysis; 2005 Nov; 16(8):549-55. PubMed ID: 16269927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant activated factor VII for acute intracerebral hemorrhage: US phase IIA trial.
    Mayer SA; Brun NC; Broderick J; Davis SM; Diringer MN; Skolnick BE; Steiner T;
    Neurocrit Care; 2006; 4(3):206-14. PubMed ID: 16757825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recombinant activated factor VII in the postanesthetic recovery unit: review of 16 cases].
    Etxániz Alvarez A; Pita Zapata E; Rama Maceiras P; Duro Tacón J; Pose Cambeiro P
    Rev Esp Anestesiol Reanim; 2006 Mar; 53(3):159-62. PubMed ID: 16671259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant activated factor VII in critical bleeding after orthotopic liver transplantation.
    Busani S; Semeraro G; Cantaroni C; Masetti M; Marietta M; Girardis M
    Transplant Proc; 2008; 40(6):1989-90. PubMed ID: 18675109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.